Zai Lab Limited (ZLAB)
| Market Cap | 2.08B -48.0% |
| Revenue (ttm) | 453.28M +8.4% |
| Net Income | -178.12M |
| EPS | -1.62 |
| Shares Out | 112.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 290,547 |
| Open | 18.39 |
| Previous Close | 18.18 |
| Day's Range | 18.31 - 18.78 |
| 52-Week Range | 15.96 - 39.64 |
| Beta | 0.76 |
| Analysts | Strong Buy |
| Price Target | 33.30 (+80.1%) |
| Earnings Date | Aug 6, 2026 |
About ZLAB
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacter... [Read more]
Financial Performance
In 2025, Zai Lab's revenue was $460.16 million, an increase of 15.33% compared to the previous year's $398.99 million. Losses were -$175.54 million, -31.73% less than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for ZLAB stock is "Strong Buy." The 12-month stock price target is $33.3, which is an increase of 80.10% from the latest price.
News
Zai Lab says FDA grants Orphan Drug Designation for zocilurtatug pelitecan
Zai Lab (ZLAB) announced the U.S. Food and Drug Administration has granted Orphan Drug Designation to zocilurtatug pelitecan, the Company’s potential first-in-class Delta-like ligand 3 antibody-drug c...
U.S. FDA Grants Orphan Drug Designation to Zai Lab's DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to zocilu...
Zai Lab treatment of neuroendocrine carcinoma granted FDA orphan designation
Zai Lab’s (ZLAB) zocilurtatug pelitecan was granted FDA orphan designation as a treatment of neuroendocrine carcinoma, according to a post to the agency’s website.
Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its second quarter 2026 financial results and provide recent corporate upda...
Insider Sell Alert: William Lis Sells 7,040 Shares of Zai Lab Ltd (ZLAB)
Insider Sell Alert: William Lis Sells 7,040 Shares of Zai Lab Ltd (ZLAB)
Zai Lab Transcript: AGM 2026
The meeting confirmed a quorum and approved all fourteen proposals, including director reelections, auditor appointments, executive compensation, and mandates for share issuance and repurchase. No shareholder questions were raised, and all resolutions passed as ordinary resolutions.
Zai Lab announces EMA granted ODD to zocilurtatug pelitecan
Zai Lab (ZLAB) announced the European Medicines Agency, EMA, has granted Orphan Drug Designation, ODD, to zocilurtatug pelitecan, the Company’s potential first-in-class Delta-like ligand 3-targeting a...
Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to zocilurtatug p...
Zai Lab (ZLAB) Gains Approval for Tivdak in Cervical Cancer Treatment
Zai Lab (ZLAB) Gains Approval for Tivdak in Cervical Cancer Treatment
Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has approved the Biologics License...
Zai Lab (ZLAB) Q1 2026 Earnings Transcript
Zai Lab (ZLAB) Q1 2026 Earnings Transcript
Zai Lab (ZLAB) Announces Leadership Change Amid Strategic Developments
Zai Lab (ZLAB) Announces Leadership Change Amid Strategic Developments
Zai Lab announces departure of COO Josh Smiley
Zai Lab (ZLAB) announced changes to its senior leadership team aimed at strengthening operational performance and efficiency. As part of these changes, the Board has made the decision that Josh…
Zai Lab Announces Changes to Senior Leadership Team
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced changes to its senior leadership team aimed at strengthening operational performance and effici...
Insider Sell Alert: Edmondson Frazor Titus III Sells Shares of Zai Lab Ltd (ZLAB)
Insider Sell Alert: Edmondson Frazor Titus III Sells Shares of Zai Lab Ltd (ZLAB)
Zai Lab (ZLAB) Achieves Fast Track Status for New Cancer Treatment
Zai Lab (ZLAB) Achieves Fast Track Status for New Cancer Treatment
Zai Lab receives FDA Fast Track Designation for zocilurtatug pelitecan
Zai Lab (ZLAB) announced the U.S. Food and Drug Administration has granted Fast Track Designation to zocilurtatug pelitecan, the Company’s potential first-in-class Delta-like ligand 3-targeting antibo...
Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to zocilurtatug ...
Zai Lab Q1 Earnings Call Highlights
Zai Lab NASDAQ: ZLAB reported a year-over-year decline in first-quarter 2026 product revenue as pressure on ZEJULA weighed on results, while management emphasized progress across its global oncology a...
Zai Lab price target lowered to $44 from $47 at Citi
Citi lowered the firm’s price target on Zai Lab (ZLAB) to $44 from $47 and keeps a Buy rating on the shares. The firm updated the company’s model post the
Zai Lab (ZLAB) Highlights Strategic Developments and Future Outlook
Zai Lab (ZLAB) Highlights Strategic Developments and Future Outlook
Zai Lab Q1 2026 Loss Widens to -$0.05/Share, Revenue Down 6%
In-line quarter. Zai Lab Limited (NASDAQ:ZLAB) posted a Q1 2026 loss per share of $0.05, matching the expected loss of $0.05, though the company faced headw... The post Zai Lab Q1 2026 Loss Widens to ...
Zai Lab Earnings Call Transcript: Q1 2026
Q1 revenue declined 6% year-over-year to $99.6M, with near-term pressure expected through 2026 and a return to growth in 2027. Pipeline advances include strong zoci data, new collaborations, and upcoming launches, supported by a robust cash position.
Zai Lab Earnings release: Q1 2026
Zai Lab released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Zai Lab Quarterly report: Q1 2026
Zai Lab has published its Q1 2026 quarterly earnings report on May 7, 2026.